-
Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort.
De Prisco M, Oliva V, Sanchez-Valle R, Parellada E, Junque C, Marti MJ, Bortolozzi A, Alberch J, Garrabou G, Sanchez-Vives MV, Giralt A, Segura B, Lladó A, Compta Y, Radua J, Vieta E, Hidalgo-Mazzei D, Anmella G. Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort. Eur Neuropsychopharmacol. 2026 Apr 20;110:112850. doi: 10.1016/j.euroneuro.2026.112850. Epub ahead of print. PMID: 42013686.
-
Glutamate-induced nuclear translocation of PYK2 in hippocampal neurons, interaction with MBD2, and role in cell death in a model of epileps
Giralt A, Mendes T, Montalban E, Cifuentes-Diaz C, Galán-Ganga M, Chouchana M, de Pins B, Longueville S, Carrel D, Girault JA. Glutamate-induced nuclear translocation of PYK2 in hippocampal neurons, interaction with MBD2, and role in cell death in a model of epilepsy. Cell Death Dis. 2026 Apr 22;17(1):535. doi: 10.1038/s41419-026-08628-x. PMID: 42020370; PMCID: PMC13237024.
-
Sex-dependent interferon signaling contributes to female-biased vulnerability in Alzheimer's disease
López-López V, Iniesta G, Galán-Ganga M, Expósito-Coca A, Durán-Laforet V, Bhojwani-Cabrera AM, Navarrón CM, Guillot-Fernández M, Venero JL, Sánchez-Mut JV, Barco A, Giralt A, López-Atalaya JP. Sex-dependent interferon signaling contributes to female-biased vulnerability in Alzheimer's disease. J Neuroinflammation. 2026 May 4. doi: 10.1186/s12974-026-03840-0. Epub ahead of print. PMID: 42083037.
-
Hippocampal small RNAs from patients with schizophrenia induce specific cognitive and neural phenotypes in mice
Galán-Ganga M, Guisado-Corcoll A, Sancho-Balsells A, Herrero-Lorenzo M, Ballasch I, Patterer L, Alberch J, Arranz B, Giralt A, Martí E. Hippocampal small RNAs from patients with schizophrenia induce specific cognitive and neural phenotypes in mice. Cell Death Discov. 2026 May 25. doi: 10.1038/s41420-026-03166-z. Epub ahead of print. PMID: 42185248.
-
Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease
Galán-Ganga, M., Rodríguez-Navarro, I., Zaballa, S. et al. Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer’s disease. Mol Biomed 7, 87 (2026). https://doi.org/10.1186/s43556-026-00481-w
-
GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia
Córdoba-Espejo L, Sánchez-Vega L, García-Ortiz A, Castellano E, Oliva R, Ortiz-Ruiz A, Gil-Alós D, Del Moral P, Fernández A, Sanjurjo D, López-García S, Perpiña U, Canals JM, Lee DA, Powell DJ Jr, Alonso R, Río P, Paciello ML, Valeri A, Leivas A, Martínez-López J. GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia. Cytotherapy. 2026 Feb;28(2):101968. doi: 10.1016/j.jcyt.2025.07.009. Epub 2025 Nov 16. PMID: 41386018.
-
The Evolving Landscape of Stem Cell Therapies for Huntington’s Disease
Estarellas, M., Gomis, C. & Canals, J.M. The Evolving Landscape of Stem Cell Therapies for Huntington’s Disease. Mol Diagn Ther (2025). https://doi.org/10.1007/s40291-025-00816-3
-
Regulatory Strategies for Accelerating the Translation of Gene Therapies to Clinical Practice: Focus on GMO Considerations
Delgadillo J, Martin F, Carmona G, Canals JM, Rio P, Eguizabal C, Prosper F, Avendaño-Solá C. Regulatory Strategies for Accelerating the Translation of Gene Therapies to Clinical Practice: Focus on GMO Considerations. Hum Gene Ther. 2025 Sep;36(17-18):1154-1158. doi: 10.1177/10430342251372063. Epub 2025 Aug 21. PMID: 40838843.
-
CD200-based cell sorting results in homogeneous transplantable striatal neuroblasts for human cell therapy for Huntington's disease.
Molina-Ruiz FJ, Sanders P, Gomis C, Abante J, Londoño F, Bombau G, Galofré M, Vinyes-Bassols G, Monforte V, Canals JM. Neurobiol Dis. (2025). DOI: 10.1016/j.nbd.2025.106905.
-
BDNF Overexpression Enhances Neuronal Activity and Axonal Growth in Human iPSC-Derived Neural Cultures
Ortega-Gasco A, Percopo F, Font-Guixe A, Ramos-Bartolome S, Cami-Bonet A, Magem-Planas M, Fabrellas-Monsech M, Esquirol-Albala E, Goulet L, Fornos-Zapater S, Arcas-Marquez A, Haeb AC, Gomez-Bravo C, Introna C, Canals JM, Tornero D. BDNF Overexpression Enhances Neuronal Activity and Axonal Growth in Human iPSC-Derived Neural Cultures. Int J Mol Sci. 2025 Jul 27;26(15):7262. doi: 10.3390/ijms26157262. PMID: 40806396; PMCID: PMC12346939.
-
Low-frequency genetic variants in GAK enhance Golgi function and protect against Parkinson's disease
Calatayud C, Fernandez-Carasa I, Spataro N, Mussolino C, Richaud-Patin Y, Faella A, Fernández-Santiago R, Ezquerra M, Courtin T, Bandres-Ciga S, Miguez A, Canals JM, Chiritoiu M, Malhotra V, Garrido A, Marti MJ, Tolosa E, Bosch E, Cathomen T, Gage FH, Raya A, Consiglio A. Low-frequency genetic variants in GAK enhance Golgi function and protect against Parkinson's disease. medRxiv [Preprint]. 2025 Aug 15:2025.08.13.25333123. doi: 10.1101/2025.08.13.25333123. PMID: 40832425; PMCID: PMC12363757.
-
La Innovació en Teràpies Avançades a Catalunya: Reptes i Oportunitats en un Ecosistema Capdavanter
A. Peiró, A. Vila, U. Perpiña, J. Canals and G. Congrés2025, La Innovació en Teràpies Avançades a Catalunya: Reptes i Oportunitats en un Ecosistema Capdavanter, 4rceec (2025). Vol. El sistema de ciència i innovació i el repte de la transformació digital, 61 URL https://www.scipedia.com/public/Peiro_et_al_2025a
-
Low-dose cannabidiol treatment prevents chronic stress-induced phenotypes and is associated with multiple synaptic changes across various brain regions.
Borràs-Pernas S, Sancho-Balsells A, Patterer L, Wang M, Del Toro D, Alberch J, Schibano D, Espel J, Heybeck M, Scheidel B, Giralt A. Neuropharmacology. (2025). DOI: 10.1016/j.neuropharm.2025.110526.
-
Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes
Ballasch I, López-Molina L, Galán-Ganga M, Sancho-Balsells A, Rodríguez-Navarro I, Borràs-Pernas S, Rabadan MA, Chen W, Pastó-Pellicer C, Flotta F, Maoyu W, Fernández-Irigoyen J, Santamaría E, Aguilar R, Dobaño C, Egri N, Hernandez C, Alfonso M, Juan M, Alberch J, Del Toro D, Arranz B, Canals JM, Giralt A. Alterations of the IKZF1-IKZF2 tandem in immune cells of schizophrenia patients regulate associated phenotypes. J Neuroinflammation. 2024 Dec 18;21(1):326.
-
Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming
Shen, Yi-Ru et al. Cell Stem Cell (2024). DOI:10.1016/j.stem.2024.09.013
-
Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease.
Miguez, A., Gomis, C., Vila, C. et al. Cell. Mol. Life Sci. 80, 238 (2023). https://doi.org/10.1007/s00018-023-04882-w
-
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV).
Sánchez-Guijo, F., Avendaño-Solá, C., Badimón, L. et al. Bone Marrow Transplant 58, 727–728 (2023). https://doi.org/10.1038/s41409-023-01962-0
-
Hyaluronic acid-based bioink improves the differentiation and network formation of neural progenitor cells.
Pereira I, Lopez-Martinez MJ, Villasante A, Introna C, Tornero D, Canals JM, Samitier J. Front Bioeng Biotechnol. 2023 Mar 3;11:1110547. doi: 10.3389/fbioe.2023.1110547.
-
Ikzf1 as a novel regulator of microglial homeostasis in inflammation and neurodegeneration.
Ballasch I, García-García E, Vila C, Pérez-González A, Sancho-Balsells A, Fernández J, Soto D, Puigdellívol M, Gasull X, Alberch J, Rodríguez MJ, Canals JM, Giralt A. Brain Behav Immun. 2023 Mar;109:144-161. doi: 10.1016/j.bbi.2023.01.016.
-
Tbr1 Misexpression Alters Neuronal Development in the Cerebral Cortex.
Crespo I, Pignatelli J, Kinare V, Méndez-Gómez HR, Esgleas M, Román MJ, Canals JM, Tole S, Vicario C. Mol Neurobiol. 2022 Sep;59(9):5750-5765. doi: 10.1007/s12035-022-02936-x.
-
Standardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs.
Molina-Ruiz FJ, Introna C, Bombau G, Galofre M, Canals JM. Cells. 2022 Jun 21;11(13):1984. doi: 10.3390/cells11131984.
-
Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder.
Rosser AE, Busse ME, Gray WP, Badin RA, Perrier AL, Wheelock V, Cozzi E, Martin UP, Salado-Manzano C, Mills LJ, Drew C, Goldman SA, Canals JM, Thompson LM. Brain. 2022 Jun 3;145(5):1584-1597. doi: 10.1093/brain/awac086.
-
Human embryonic mesenchymal lung-conditioned medium promotes differentiation to myofibroblast and loss of stemness phenotype in lung adenocarcinoma cell lines.
Canals J, Navarro A, Vila C, Canals JM, Díaz T, Acosta-Plasencia M, Cros-Font C, Han B, He Y, Monzó M. J Exp Clin Cancer Res 41, 37 (2022). https://doi.org/10.1186/s13046-021-02206-z
-
Cell Therapy for Huntington's Disease: Learning from Failure.
Rosser AE, Busse M, Aron Badin R, Canals JM, Wheelock V, Perrier AL, Gray W, Thompson L, Goldman S. Mov Disord. 2021 Mar;36(3):787-788. doi: 10.1002/mds.28503.
-
Stem Cells for Huntington's Disease (SC4HD): An International Consortium to Facilitate Stem Cell-Based Therapy for Huntington's Disease.
SC4HD Consortium. J Huntingtons Dis. 2021;10(2):221-226. doi: 10.3233/JHD-210473.
-
Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
Leal L, Couto E, Sánchez-Palomino S, Climent N, Fernández I, Miralles L, Romero Y, González T, Maleno MJ, Paño B, Pich J, Nicolau C, Gatell JM, Plana M, García F. Front Immunol. 2021 Nov 11;12:767370. doi: 10.3389/fimmu.2021.767370.
-
Decreased Myocyte Enhancer Factor 2 Levels in the Hippocampus of Huntington's Disease Mice Are Related to Cognitive Dysfunction.
Vidal-Sancho L, Fernández-García S, Solés-Tarrés I, Alberch J, Xifró X. Mol Neurobiol. 2020 57(11):4549-4562.
-
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 + Relapsed/Refractory Malignancies.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, Torrebadell M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordan I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan M, Delgado J. Mol Ther. 2021 Feb 3;29(2):636-644. doi: 10.1016/j.ymthe.2020.09.027.
-
Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?
Salado-Manzano C, Perpiña U, Straccia M, Molina-Ruiz FJ, Cozzi E, Rosser AE, Canals JM. Front Cell Neurosci. 2020 Aug 11;14:250. doi: 10.3389/fncel.2020.00250.
-
Advanced Non-animal Models in Biomedical Research – Immunogenicity testing for advanced therapy medicinal products.
Canals, J. M., Romania, P., Belio-Mairal P., Nic, M., Dibusz, K., Novotny, T., Busquet, F., Rossi, F., Straccia, M., Daskalopoulos, E. P., and Gribaldo, L. EUR 30334/4 EN, Publications Office of the European Union, Luxembourg, 2022, ISBN 978-92-76-49091-3. doi:10.2760/7190, JRC126997.
-
Advanced Non-animal Models in Biomedical Research - Autoimmune Diseases.
Juan, M., Canals, J.M., Belio-Mairal, P., Nic, M., Dibusz, K., Novotny, T., Busquet, F., Rossi, F., Gastaldello, A., Gribaldo, L., Straccia, M., Dura, A. and Whelan, M. EUR 30334/6 EN, Publications Office of the European Union, Luxembourg, 2022, ISBN 978-92-76-58966-2
-
Advanced Therapy Medicinal Products.
Meij P., Canals, J.M., Lowery M., Scott M. LERU Briefing paper. 2019 September.